Here, we observed that similarly, the combination of anti-VEGF with Pemetrexed/Cisplatin doublet plus anti-PD-1 showed better efficacy when optimal sequencing was used, as tumor volume reduction improved from -55% with concurrent dosing to -71% with sequential dosing. The gene discussed is VEGFA; the disease is neoplasm.